Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection

J. J M Holthuis, F. M G M Römkens, H. M. Pinedo, W. J. Van Oort

Research output: Contribution to journalArticle

Abstract

A sensitive high-performance liquid chromatographic (HPLC) assay of the antineoplastic agent VP 16-213 (etoposide) in plasma is described. The system discriminates between the parent compound and possible metabolites, including the aglycone and the cis isomer. After extraction with 1,2-dichloroethane the drugs are chromatographed on a reversed-phase phenyl column with amperometric detection. Quantitative response is linear up to 250 ng/ml for 1 ml human plasma and up to 40.0 μg/ml for 0.1 ml human plasma. The detection limit is ca 2 ng/ml in plasma. Preliminary pharmacokinetic results show that the sensitivity and selectivity of the assay are adequate to establish plasma concentrations over 8-12 half-lives during elimination of the drug.

Original languageEnglish (US)
Pages (from-to)89-97
Number of pages9
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume1
Issue number1
DOIs
StatePublished - 1983
Externally publishedYes

Keywords

  • anti-tumour agents
  • electrochemical chromatographic detection.
  • etoposide
  • High-performance liquid chromatography

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection'. Together they form a unique fingerprint.

  • Cite this